Browsing by Author "Ahsan, Fakhrul"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension
    (American Physiological Society, 2021-06) Hye, Tanvirul; Dwivedi, Pankaj; Li, Wei; Lahm, Tim; Nozik-Grayck, Eva; Stenmark, Kurt R.; Ahsan, Fakhrul; Medicine, School of Medicine
    Pulmonary arterial hypertension (PAH) affects more women than men, although affected females tend to survive longer than affected males. This sex disparity in PAH is postulated to stem from the diverse roles of sex hormones in disease etiology. In animal models, estrogens appear to be implicated not only in pathologic remodeling of pulmonary arteries, but also in protection against right ventricular (RV) hypertrophy. In contrast, the male sex hormone testosterone is associated with reduced survival in male animals, where it is associated with increased RV mass, volume, and fibrosis. However, it also has a vasodilatory effect on pulmonary arteries. Furthermore, patients of both sexes show varying degrees of response to current therapies for PAH. As such, there are many gaps and contradictions regarding PAH development, progression, and therapeutic interventions in male versus female patients. Many of these questions remain unanswered, which may be due in part to lack of effective experimental models that can consistently reproduce PAH pulmonary microenvironments in their sex-specific forms. This review article summarizes the roles of estrogens and related sex hormones, immunological and genetical differences, and the benefits and limitations of existing experimental tools to fill in gaps in our understanding of the sex-based variation in PAH development and progression. Finally, we highlight the potential of a new tissue chip-based model mimicking PAH-afflicted male and female pulmonary arteries to study the sex-based differences in PAH and to develop personalized therapies based on patient sex and responsiveness to existing and new drugs.
  • Thumbnail Image
    Item
    Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application
    (The Royal Society of Chemistry, 2020-07-28) Al-Hilal, Taslim A.; Keshavarz, Ali; Kadry, Hossam; Lahooti, Behnaz; Al-Obaida, Ahmed; Ding, Zhenya; Li, Wei; Kamm, Roger; McMurtry, Ivan F.; Lahm, Tim; Nozik-Grayck, Eva; Stenmark, Kurt R.; Ahsan, Fakhrul; Anatomy and Cell Biology, School of Medicine
    Currently used animal and cellular models for pulmonary arterial hypertension (PAH) only partially recapitulate its pathophysiology in humans and are thus inadequate in reproducing the hallmarks of the disease, inconsistent in portraying the sex-disparity, and unyielding to combinatorial study designs. Here we sought to deploy the ingenuity of microengineering in developing and validating a tissue chip model for human PAH. We designed and fabricated a microfluidic device to emulate the luminal, intimal, medial, adventitial, and perivascular layers of a pulmonary artery. By growing three types of pulmonary arterial cells (PACs)-endothelial, smooth muscle, and adventitial cells, we recreated the PAH pathophysiology on the device. Diseased (PAH) PACs, when grown on the chips, moved of out their designated layers and created phenomena similar to the major pathologies of human PAH: intimal thickening, muscularization, and arterial remodeling and show an endothelial to mesenchymal transition. Flow-induced stress caused control cells, grown on the chips, to undergo morphological changes and elicit arterial remodeling. Our data also suggest that the newly developed chips can be used to elucidate the sex disparity in PAH and to study the therapeutic efficacy of existing and investigational anti-PAH drugs. We believe this miniaturized device can be deployed for testing various prevailing and new hypotheses regarding the pathobiology and drug therapy in human PAH.